MaRS Innovation announced today the second project to be developed under their LAB150 partnership with Evotec. The project aims to develop a novel therapeutic approach to treat glaucoma, an irreversible neurodegenerative disease of the optic nerve which can lead to blindness. This project is derived from a decade of research investigating the molecular pathways underlying tissue damage and repair in the eye in the laboratory of Dr. Jeremy Sivak, Senior Scientist at UHN’s Krembil Research Institute, in Toronto. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab150-awards-its-second-drug-discovery-project-from-canadas-largest-research-based-hospital-the-university-health-network-uhn-5731